ArticleAmerican journal of translational research2026
Evaluation of treatment for acute hexavalent chromium poisoning in human renal proximal tubular epithelial cells with 2,3-dimercapto-1-propanesulfonic acid (DMPS).
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesChelating agents have been utilized in clinical settings to counteract various heavy metal poisonings, although there are currently no established medical guidelines supporting the use of the chelating agent 2,3-dimercapto-1-propanesulfonic acid (DMPS) for treating acute hexavalent chromium (Cr(VI)) poisoning.
methodsSince systemic acute Cr(VI) poisoning has been associated with nephrotoxicity in clinical cases, this study utilized the immortalized human renal epithelial cell line HK-2 and primary proximal tubular epithelial cells (RPTEC) as
resultsIn the HK-2 cell model, cell viability dropped below 50% after exposure to 10 μmol/L Cr(VI) for 32 hours. Both simultaneous administration of 10 μmol/L Cr(VI) with 100 or 300 μg/mL DMPS and delayed treatment with DMPS after two hours effectively reduced Cr(VI)-induced cell death. Furthermore, in the RPTEC cell model, DMPS treatments ranging from 300 to 1000 μg/mL demonstrated significant protective effects on cell viability against Cr(VI) toxicity, mirroring the results observed in the HK-2 model. In contrast, meso-2,3-dimercaptosuccinic acid, another chelating agent, did not exhibit protective effects on HK-2 cells.
conclusionsThese findings support DMPS as a promising antidote for acute Cr(VI) poisoning in kidney cells and provide valuable insights for potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.